本文選題：過(guò)敏性紫癜 + 涼血健脾法�。� 參考：《福建中醫(yī)藥大學(xué)》2012年碩士論文

【摘要】：目的：觀察對(duì)比西藥常規(guī)治療與加用涼血健脾中藥治療過(guò)敏性紫癜(Henoch-Schonlein purpura, HSP)患兒的臨床療效,及加入涼血健脾中藥后對(duì)HSP患兒血清白三烯B4(Leukotriene B4, LTB4)、血管內(nèi)皮生長(zhǎng)因子(Vascular endothelial growth factor,VEGF)的影響,探討涼血健脾法治療HSP的臨床療效及機(jī)制。 方法：選擇符合入選標(biāo)準(zhǔn)的HSP患兒60例、健康同齡兒童30例(為同期于福建省立醫(yī)院兒科門(mén)診體檢的健康兒童)。將HSP患兒隨機(jī)分為西藥組30例(采用西藥常規(guī)治療)和中西藥組30例(加用涼血健脾中藥治療),分別觀察兩組臨床療效、臨床癥狀改善時(shí)間、復(fù)發(fā)率。同時(shí)分別收集兩組患兒治療前后的血液,離心取血清后冷凍保存,用酶聯(lián)免疫吸附法(ELISA)檢測(cè)血清中LTB4、VEGF水平。對(duì)比兩組治療前后患兒血清LTB4、VEGF水平的差異,同時(shí)與健康同齡兒相比較。 結(jié)果：①加用涼血健脾中藥治療的中西藥組30例HSP患兒總顯效率86.67%,優(yōu)于常規(guī)西藥治療對(duì)照組63.33%(P=0.036)。②中西藥治療組總復(fù)發(fā)率9.99%,低于西藥對(duì)照組16.66%(P=0.029)。③中西藥治療組臨床癥狀(皮疹、關(guān)節(jié)痛、便血)改善起效時(shí)間分別為(6.73-±-3.40、3.24±1.64、1.88±0.83)天,明顯短于西藥對(duì)照組(9.43±3.95、3.29±1.20、4.71±-2.69)天,P均0.05。④中西藥治療組治療后血清LTB4、VEGF水平低于西藥常規(guī)治療組(P均0.05),差異顯著。 結(jié)論：涼血健脾法治療HSP患兒療效顯著,可抑制HSP患兒血清LTB4、VEGF水平,有一定的抗炎、保護(hù)內(nèi)皮細(xì)胞作用,而達(dá)到輔助治療HSP的療效。
[Abstract]:Objective: To observe and compare the clinical efficacy of traditional western medicine and traditional Chinese medicine with cold blood and invigorating spleen for Henoch-Schonlein purpura (HSP), and the effect of adding cold blood and invigorating spleen on serum leukotriene B4 (Leukotriene B4, LTB4) and vascular endothelial Naga Innoko (Vascular endothelial growth factor) in children with HSP. Objective to investigate the clinical efficacy and mechanism of cooling blood and invigorating spleen in treating HSP.
Methods: 60 children with HSP and 30 healthy children of the same age were selected. The children were randomly divided into 30 cases of Western medicine group (30 cases of Western Medicine) and 30 cases of Chinese and Western Medicine (traditional Chinese medicine treatment). The clinical effects and clinical symptoms of the two groups were observed and the clinical symptoms were observed. At the same time, the blood of two groups of children before and after treatment were collected, and the serum levels of LTB4 and VEGF were detected by enzyme linked immunosorbent assay (ELISA). The difference of serum LTB4 and VEGF levels between the two groups before and after treatment was compared with those of the same age children.
Results: (1) the total effective rate of 30 children with Chinese and Western medicine treated with traditional Chinese medicine and traditional Chinese medicine was 86.67%, superior to that of the conventional western medicine treatment control group (63.33% (P=0.036)). The total recurrence rate of the Chinese and Western medicine treatment group was 9.99%, lower than that of the western medicine control group (16.66% (P=0.029)). (3) the improvement of the onset time of the clinical symptoms (rash, joint pain, and stool) in the treatment group of Chinese and Western Medicine (P=0.029). (6.73- + -3.40,3.24 + 1.64,1.88 + 0.83) days, significantly shorter than the western medicine control group (9.43 + 3.95,3.29 + 1.20,4.71 + -2.69) days, P 0.05. (4) in the western medicine treatment group after treatment, the serum LTB4, VEGF level was lower than the western medicine routine treatment group (P 0.05), the difference was significant.
Conclusion: the treatment of HSP in children with cold blood and invigorating spleen is effective. It can inhibit the serum level of LTB4 and VEGF in children with HSP, and it has some anti-inflammatory and protective effect on endothelial cells, and it can be used to assist in the treatment of HSP.
【學(xué)位授予單位】：福建中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2012
【分類(lèi)號(hào)】：R725.5

【參考文獻(xiàn)】

相關(guān)期刊論文 前1條

1 肖達(dá)民;中醫(yī)藥治療過(guò)敏性紫癜的思路與方法[J];新中醫(yī);2001年12期

，

本文編號(hào)：2098106